Compare Stocks

4 / 10
Try these comparisons:

Stock Comparison

RMD vs ITGR vs NVCR vs LIVN

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
RMD
ResMed Inc.

Medical - Instruments & Supplies

HealthcareNYSE • US
Market Cap$30.15B
5Y Perf.+28.7%
ITGR
Integer Holdings Corporation

Medical - Devices

HealthcareNYSE • US
Market Cap$3.03B
5Y Perf.+11.0%
NVCR
NovoCure Limited

Medical - Instruments & Supplies

HealthcareNASDAQ • JE
Market Cap$1.92B
5Y Perf.-75.0%
LIVN
LivaNova PLC

Medical - Devices

HealthcareNASDAQ • GB
Market Cap$3.88B
5Y Perf.+32.6%

RMD vs ITGR vs NVCR vs LIVN — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
RMD logoRMD
ITGR logoITGR
NVCR logoNVCR
LIVN logoLIVN
IndustryMedical - Instruments & SuppliesMedical - DevicesMedical - Instruments & SuppliesMedical - Devices
Market Cap$30.15B$3.03B$1.92B$3.88B
Revenue (TTM)$5.54B$1.85B$674M$1.43B
Net Income (TTM)$1.52B$142M$-173M$107M
Gross Margin61.7%23.3%75.2%67.5%
Operating Margin34.3%10.4%-27.2%13.4%
Forward P/E18.8x13.5x16.8x
Total Debt$852M$1.40B$290M$473M
Cash & Equiv.$1.21B$17M$103M$636M

RMD vs ITGR vs NVCR vs LIVNLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

RMD
ITGR
NVCR
LIVN
StockMay 20May 26Return
ResMed Inc. (RMD)100128.7+28.7%
Integer Holdings Co… (ITGR)100111.0+11.0%
NovoCure Limited (NVCR)10025.0-75.0%
LivaNova PLC (LIVN)100132.6+32.6%

Price return only. Dividends and distributions are not included.

Quick Verdict: RMD vs ITGR vs NVCR vs LIVN

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: RMD leads in 5 of 7 categories, making it the strongest pick for valuation and capital efficiency and profitability and margin quality. LivaNova PLC is the stronger pick specifically for growth and revenue expansion and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
RMD
ResMed Inc.
The Income Pick

RMD carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.

  • Dividend streak 14 yrs, beta 0.66, yield 1.0%
  • Rev growth 9.8%, EPS growth 37.4%, 3Y rev CAGR 12.9%
  • 293.8% 10Y total return vs ITGR's 165.1%
  • Lower volatility, beta 0.66, Low D/E 14.3%, current ratio 3.44x
Best for: income & stability and growth exposure
ITGR
Integer Holdings Corporation
The Lower-Volatility Pick

ITGR plays a supporting role in this comparison — it may shine differently against other peers.

Best for: healthcare exposure
NVCR
NovoCure Limited
The Secondary Option

NVCR lags the leaders in this set but could rank higher in a more targeted comparison.

Best for: healthcare exposure
LIVN
LivaNova PLC
The Growth Leader

LIVN is the #2 pick in this set and the best alternative if growth and momentum is your priority.

  • 10.7% revenue growth vs ITGR's 7.6%
  • +63.0% vs ITGR's -26.1%
Best for: growth and momentum
See the full category breakdown
CategoryWinnerWhy
GrowthLIVN logoLIVN10.7% revenue growth vs ITGR's 7.6%
ValueRMD logoRMDBetter valuation composite
Quality / MarginsRMD logoRMD27.4% margin vs NVCR's -25.7%
Stability / SafetyRMD logoRMDBeta 0.66 vs NVCR's 2.20, lower leverage
DividendsRMD logoRMD1.0% yield; 14-year raise streak; the other 3 pay no meaningful dividend
Momentum (1Y)LIVN logoLIVN+63.0% vs ITGR's -26.1%
Efficiency (ROA)RMD logoRMD18.0% ROA vs NVCR's -16.5%, ROIC 22.8% vs -16.4%

RMD vs ITGR vs NVCR vs LIVN — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

RMDResMed Inc.
FY 2024
Sleep And Respiratory
87.5%$4.1B
Software As Service
12.5%$584M
ITGRInteger Holdings Corporation
FY 2025
Cardio And Vascular
59.7%$1.1B
Cardiac Rhythm Management & Neuromodulation
36.1%$669M
Other Markets
4.2%$78M
NVCRNovoCure Limited

Segment breakdown not available.

LIVNLivaNova PLC
FY 2025
Cardiopulmonary Segment
57.0%$785M
Neuromodulation Segment
43.0%$593M

RMD vs ITGR vs NVCR vs LIVN — Financial Metrics

Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLRMDLAGGINGNVCR

Income & Cash Flow (Last 12 Months)

RMD leads this category, winning 3 of 6 comparable metrics.

RMD is the larger business by revenue, generating $5.5B annually — 8.2x NVCR's $674M. RMD is the more profitable business, keeping 27.4% of every revenue dollar as net income compared to NVCR's -25.7%. On growth, LIVN holds the edge at +14.3% YoY revenue growth, suggesting stronger near-term business momentum.

MetricRMD logoRMDResMed Inc.ITGR logoITGRInteger Holdings …NVCR logoNVCRNovoCure LimitedLIVN logoLIVNLivaNova PLC
RevenueTrailing 12 months$5.5B$1.8B$674M$1.4B
EBITDAEarnings before interest/tax$2.1B$328M-$165M$220M
Net IncomeAfter-tax profit$1.5B$142M-$173M$107M
Free Cash FlowCash after capex$1.8B$168M-$48M$161M
Gross MarginGross profit ÷ Revenue+61.7%+23.3%+75.2%+67.5%
Operating MarginEBIT ÷ Revenue+34.3%+10.4%-27.2%+13.4%
Net MarginNet income ÷ Revenue+27.4%+7.7%-25.7%+7.5%
FCF MarginFCF ÷ Revenue+31.7%+9.1%-7.1%+11.2%
Rev. Growth (YoY)Latest quarter vs prior year+10.8%+0.8%+12.3%+14.3%
EPS Growth (YoY)Latest quarter vs prior year+9.3%+172.7%-100.0%+106.7%
RMD leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

ITGR leads this category, winning 4 of 7 comparable metrics.

At 21.8x trailing earnings, RMD trades at a 28% valuation discount to ITGR's 30.4x P/E. Adjusting for growth (PEG ratio), RMD offers better value at 1.25x vs ITGR's 6.91x — a lower PEG means you pay less per unit of expected earnings growth.

MetricRMD logoRMDResMed Inc.ITGR logoITGRInteger Holdings …NVCR logoNVCRNovoCure LimitedLIVN logoLIVNLivaNova PLC
Market CapShares × price$30.1B$3.0B$1.9B$3.9B
Enterprise ValueMkt cap + debt − cash$29.8B$4.4B$2.1B$3.7B
Trailing P/EPrice ÷ TTM EPS21.76x30.42x-13.80x-15.94x
Forward P/EPrice ÷ next-FY EPS est.18.78x13.55x16.84x
PEG RatioP/E ÷ EPS growth rate1.25x6.91x
EV / EBITDAEnterprise value multiple15.51x13.15x15.40x
Price / SalesMarket cap ÷ Revenue5.86x1.64x2.92x2.79x
Price / BookPrice ÷ Book value/share5.11x1.79x5.51x3.22x
Price / FCFMarket cap ÷ FCF18.14x28.78x22.40x
ITGR leads this category, winning 4 of 7 comparable metrics.

Profitability & Efficiency

RMD leads this category, winning 8 of 9 comparable metrics.

RMD delivers a 24.4% return on equity — every $100 of shareholder capital generates $24 in annual profit, vs $-51 for NVCR. RMD carries lower financial leverage with a 0.14x debt-to-equity ratio, signaling a more conservative balance sheet compared to NVCR's 0.85x. On the Piotroski fundamental quality scale (0–9), RMD scores 8/9 vs LIVN's 5/9, reflecting strong financial health.

MetricRMD logoRMDResMed Inc.ITGR logoITGRInteger Holdings …NVCR logoNVCRNovoCure LimitedLIVN logoLIVNLivaNova PLC
ROE (TTM)Return on equity+24.4%+8.2%-50.8%+9.1%
ROA (TTM)Return on assets+18.0%+4.2%-16.5%+4.2%
ROICReturn on invested capital+22.8%+5.4%-16.4%+11.5%
ROCEReturn on capital employed+25.7%+6.9%-28.9%+10.2%
Piotroski ScoreFundamental quality 0–98555
Debt / EquityFinancial leverage0.14x0.80x0.85x0.39x
Net DebtTotal debt minus cash-$358M$1.4B$187M-$162M
Cash & Equiv.Liquid assets$1.2B$17M$103M$636M
Total DebtShort + long-term debt$852M$1.4B$290M$473M
Interest CoverageEBIT ÷ Interest expense66.06x5.07x-96.80x3.98x
RMD leads this category, winning 8 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

LIVN leads this category, winning 3 of 6 comparable metrics.

A $10,000 investment in RMD five years ago would be worth $11,100 today (with dividends reinvested), compared to $875 for NVCR. Over the past 12 months, LIVN leads with a +63.0% total return vs ITGR's -26.1%. The 3-year compound annual growth rate (CAGR) favors LIVN at 14.6% vs NVCR's -37.6% — a key indicator of consistent wealth creation.

MetricRMD logoRMDResMed Inc.ITGR logoITGRInteger Holdings …NVCR logoNVCRNovoCure LimitedLIVN logoLIVNLivaNova PLC
YTD ReturnYear-to-date-15.2%+14.5%+28.3%+17.0%
1-Year ReturnPast 12 months-14.5%-26.1%+1.1%+63.0%
3-Year ReturnCumulative with dividends-8.4%+8.8%-75.7%+50.5%
5-Year ReturnCumulative with dividends+11.0%-7.5%-91.3%-14.5%
10-Year ReturnCumulative with dividends+293.8%+165.1%+30.3%+46.2%
CAGR (3Y)Annualised 3-year return-2.9%+2.9%-37.6%+14.6%
LIVN leads this category, winning 3 of 6 comparable metrics.

Risk & Volatility

Evenly matched — RMD and LIVN each lead in 1 of 2 comparable metrics.

RMD is the less volatile stock with a 0.66 beta — it tends to amplify market swings less than NVCR's 2.20 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. LIVN currently trades 98.6% from its 52-week high vs RMD's 70.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricRMD logoRMDResMed Inc.ITGR logoITGRInteger Holdings …NVCR logoNVCRNovoCure LimitedLIVN logoLIVNLivaNova PLC
Beta (5Y)Sensitivity to S&P 5000.66x0.72x2.20x1.29x
52-Week HighHighest price in past year$293.81$123.78$20.06$71.92
52-Week LowLowest price in past year$198.64$62.00$9.82$39.36
% of 52W HighCurrent price vs 52-week peak+70.4%+71.0%+83.9%+98.6%
RSI (14)Momentum oscillator 0–10035.650.969.857.6
Avg Volume (50D)Average daily shares traded1.1M628K1.5M808K
Evenly matched — RMD and LIVN each lead in 1 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Analyst consensus: RMD as "Buy", ITGR as "Buy", NVCR as "Buy", LIVN as "Buy". Consensus price targets imply 99.0% upside for NVCR (target: $34) vs 7.0% for LIVN (target: $76). RMD is the only dividend payer here at 1.02% yield — a key consideration for income-focused portfolios.

MetricRMD logoRMDResMed Inc.ITGR logoITGRInteger Holdings …NVCR logoNVCRNovoCure LimitedLIVN logoLIVNLivaNova PLC
Analyst RatingConsensus buy/hold/sellBuyBuyBuyBuy
Price TargetConsensus 12-month target$281.29$98.00$33.50$75.88
# AnalystsCovering analysts35141514
Dividend YieldAnnual dividend ÷ price+1.0%
Dividend StreakConsecutive years of raises14
Dividend / ShareAnnual DPS$2.11
Buyback YieldShare repurchases ÷ mkt cap+1.0%+1.7%0.0%+0.1%
Insufficient data to determine a leader in this category.
Key Takeaway

RMD leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). ITGR leads in 1 (Valuation Metrics). 1 tied.

Best OverallResMed Inc. (RMD)Leads 2 of 6 categories
Loading custom metrics...

RMD vs ITGR vs NVCR vs LIVN: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is RMD or ITGR or NVCR or LIVN a better buy right now?

For growth investors, LivaNova PLC (LIVN) is the stronger pick with 10.

7% revenue growth year-over-year, versus 7. 6% for Integer Holdings Corporation (ITGR). ResMed Inc. (RMD) offers the better valuation at 21. 8x trailing P/E (18. 8x forward), making it the more compelling value choice. Analysts rate ResMed Inc. (RMD) a "Buy" — based on 35 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — RMD or ITGR or NVCR or LIVN?

On trailing P/E, ResMed Inc.

(RMD) is the cheapest at 21. 8x versus Integer Holdings Corporation at 30. 4x. On forward P/E, Integer Holdings Corporation is actually cheaper at 13. 5x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: ResMed Inc. wins at 1. 08x versus Integer Holdings Corporation's 3. 08x — a reasonable growth-adjusted valuation.

03

Which is the better long-term investment — RMD or ITGR or NVCR or LIVN?

Over the past 5 years, ResMed Inc.

(RMD) delivered a total return of +11. 0%, compared to -91. 3% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: RMD returned +293. 8% versus NVCR's +30. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — RMD or ITGR or NVCR or LIVN?

By beta (market sensitivity over 5 years), ResMed Inc.

(RMD) is the lower-risk stock at 0. 66β versus NovoCure Limited's 2. 20β — meaning NVCR is approximately 236% more volatile than RMD relative to the S&P 500. On balance sheet safety, ResMed Inc. (RMD) carries a lower debt/equity ratio of 14% versus 85% for NovoCure Limited — giving it more financial flexibility in a downturn.

05

Which is growing faster — RMD or ITGR or NVCR or LIVN?

By revenue growth (latest reported year), LivaNova PLC (LIVN) is pulling ahead at 10.

7% versus 7. 6% for Integer Holdings Corporation (ITGR). On earnings-per-share growth, the picture is similar: ResMed Inc. grew EPS 37. 4% year-over-year, compared to -483. 6% for LivaNova PLC. Over a 3-year CAGR, RMD leads at 12. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — RMD or ITGR or NVCR or LIVN?

ResMed Inc.

(RMD) is the more profitable company, earning 27. 2% net margin versus -20. 8% for NovoCure Limited — meaning it keeps 27. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RMD leads at 32. 7% versus -23. 5% for NVCR. At the gross margin level — before operating expenses — NVCR leads at 74. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is RMD or ITGR or NVCR or LIVN more undervalued right now?

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, ResMed Inc. (RMD) is the more undervalued stock at a PEG of 1. 08x versus Integer Holdings Corporation's 3. 08x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Integer Holdings Corporation (ITGR) trades at 13. 5x forward P/E versus 18. 8x for ResMed Inc. — 5. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NVCR: 99. 0% to $33. 50.

08

Which pays a better dividend — RMD or ITGR or NVCR or LIVN?

In this comparison, RMD (1.

0% yield) pays a dividend. ITGR, NVCR, LIVN do not pay a meaningful dividend and should not be held primarily for income.

09

Is RMD or ITGR or NVCR or LIVN better for a retirement portfolio?

For long-horizon retirement investors, ResMed Inc.

(RMD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 66), 1. 0% yield, +293. 8% 10Y return). NovoCure Limited (NVCR) carries a higher beta of 2. 20 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (RMD: +293. 8%, NVCR: +30. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between RMD and ITGR and NVCR and LIVN?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

RMD pays a dividend while ITGR, NVCR, LIVN do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

RMD

Quality Mega-Cap Compounder

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 16%
Run This Screen
Stocks Like

ITGR

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 5%
Run This Screen
Stocks Like

NVCR

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 6%
  • Gross Margin > 45%
Run This Screen
Stocks Like

LIVN

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 7%
  • Net Margin > 5%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform RMD and ITGR and NVCR and LIVN on the metrics below

Revenue Growth>
%
(RMD: 10.8% · ITGR: 0.8%)
Net Margin>
%
(RMD: 27.4% · ITGR: 7.7%)
P/E Ratio<
x
(RMD: 21.8x · ITGR: 30.4x)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.